Loading quotes...
Forecast
The analysts' average price target is €30.48 (+76.70%). The median is €30.48 (+76.70%).
| Buy |
10 |
| Hold |
3 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Vor Biopharma advances telitacicept pipeline after Citigroup biopharma summit
Vor Biopharma presented an accelerated development and commercialization strategy for telitacicept at the Citigroup biopharma summit. Recruitment for the Phase III study in myasthenia gravis was completed early; topline data are expected in the first half of 2027. A Phase III study for ocular myasthenia gravis is planned to start in H1 2027, and the Sjögren’s study is recruiting more strongly than expected. The company emphasizes the broad potential of the BAFF-/APRIL inhibitor, based on experience in China with more than 10,000 treated patients, and is now focusing on regulatory preparation, manufacturing and commercial readiness. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -76.57m | 88.94% |
| EBITDA | -76.53m | 88.95% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €957.3m |
Number of shares | 54.19m |
52-week high/low | €23.65 - €5.91 |
| Dividends | No |
Beta | 1.83 |
P/E ratio | 0.06 |
PEG ratio | 0.00 |
P/B ratio | -8.45 |
P/S ratio | 0.00 |
Company profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Name | Vor Biopharma |
| CEO | Jean-Paul Kress |
| Website | |
| IPO | 05/02/2021 |
| Employees | 76 |